JP2018502900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502900A5 JP2018502900A5 JP2017540966A JP2017540966A JP2018502900A5 JP 2018502900 A5 JP2018502900 A5 JP 2018502900A5 JP 2017540966 A JP2017540966 A JP 2017540966A JP 2017540966 A JP2017540966 A JP 2017540966A JP 2018502900 A5 JP2018502900 A5 JP 2018502900A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyrimidin
- phenyl
- carboxamide
- tetrahydroisoquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 102
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- -1 hydroxy, hydroxysulfonyl Chemical group 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 108010043648 Discoidin Domain Receptors Proteins 0.000 claims description 4
- 102000002706 Discoidin Domain Receptors Human genes 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 4
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 4
- 201000002793 renal fibrosis Diseases 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- YXESXLYKZKCWFJ-IBGZPJMESA-N (4R)-4-methyl-N-[3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound C[C@H]1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(CN2CCN(C)CC2)=CC(=C1)C(F)(F)F)C1=CN=CN=C1 YXESXLYKZKCWFJ-IBGZPJMESA-N 0.000 claims description 3
- YXESXLYKZKCWFJ-LJQANCHMSA-N (4S)-4-methyl-N-[3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound C[C@@H]1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(CN2CCN(C)CC2)=CC(=C1)C(F)(F)F)C1=CN=CN=C1 YXESXLYKZKCWFJ-LJQANCHMSA-N 0.000 claims description 3
- GCCXSOBNEILODC-UHFFFAOYSA-N 3-methyl-N-[3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CC2=C(CN1C1=CN=CN=C1)C=C(C=C2)C(=O)NC1=CC(CN2CCN(C)CC2)=CC(=C1)C(F)(F)F GCCXSOBNEILODC-UHFFFAOYSA-N 0.000 claims description 3
- FBZZFRZOFAPOOA-UHFFFAOYSA-N 4,4-dimethyl-N-[3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-1,3-dihydroisoquinoline-7-carboxamide Chemical compound CN1CCN(CC2=CC(=CC(NC(=O)C3=CC4=C(C=C3)C(C)(C)CN(C4)C3=CN=CN=C3)=C2)C(F)(F)F)CC1 FBZZFRZOFAPOOA-UHFFFAOYSA-N 0.000 claims description 3
- DGYSAXDYYWORIW-UHFFFAOYSA-N 4-ethyl-N-[3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CCC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(CN2CCN(C)CC2)=CC(=C1)C(F)(F)F)C1=CN=CN=C1 DGYSAXDYYWORIW-UHFFFAOYSA-N 0.000 claims description 3
- JETMDPCRAJXEPR-UHFFFAOYSA-N 4-methyl-2-pyrimidin-5-yl-N-[3-(pyrrolidin-1-ylmethyl)-5-(trifluoromethyl)phenyl]-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(CN2CCCC2)=CC(=C1)C(F)(F)F)C1=CN=CN=C1 JETMDPCRAJXEPR-UHFFFAOYSA-N 0.000 claims description 3
- AQMFOKWCFVBZJQ-UHFFFAOYSA-N 4-methyl-2-pyrimidin-5-yl-N-[3-(thiomorpholin-4-ylmethyl)-5-(trifluoromethyl)phenyl]-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=CC(=CC=C12)C(=O)NC1=CC(=CC(=C1)C(F)(F)F)CN1CCSCC1)C=1C=NC=NC=1 AQMFOKWCFVBZJQ-UHFFFAOYSA-N 0.000 claims description 3
- INRQRAGIFFPFRI-UHFFFAOYSA-N 4-methyl-2-pyrimidin-5-yl-N-[3-(trifluoromethyl)phenyl]-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=CC(=CC=C12)C(=O)NC1=CC(=CC=C1)C(F)(F)F)C=1C=NC=NC=1 INRQRAGIFFPFRI-UHFFFAOYSA-N 0.000 claims description 3
- CMJJZRAAQMUAFH-UHFFFAOYSA-N 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(=CC(=C1)C(F)(F)F)N1C=NC(C)=C1)C1=CN=CN=C1 CMJJZRAAQMUAFH-UHFFFAOYSA-N 0.000 claims description 3
- JJFZFULVGZVWGT-UHFFFAOYSA-N 4-methyl-N-[3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(=CC(=C1)C(F)(F)F)N1CCN(C)CC1)C1=CN=CN=C1 JJFZFULVGZVWGT-UHFFFAOYSA-N 0.000 claims description 3
- KPHQVVGDSUOKRN-UHFFFAOYSA-N 4-methyl-N-[3-(morpholin-4-ylmethyl)-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(CN2CCOCC2)=CC(=C1)C(F)(F)F)C1=CN=CN=C1 KPHQVVGDSUOKRN-UHFFFAOYSA-N 0.000 claims description 3
- XOLAOFXBPNDMTP-UHFFFAOYSA-N 4-methyl-N-[3-(piperidin-1-ylmethyl)-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(CN2CCCCC2)=CC(=C1)C(F)(F)F)C1=CN=CN=C1 XOLAOFXBPNDMTP-UHFFFAOYSA-N 0.000 claims description 3
- DDPFCUXJEFSBMK-UHFFFAOYSA-N 4-methyl-N-[3-[(4-methyl-1,4-diazepan-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(CN2CCCN(C)CC2)=CC(=C1)C(F)(F)F)C1=CN=CN=C1 DDPFCUXJEFSBMK-UHFFFAOYSA-N 0.000 claims description 3
- DXOMFAFXHKRMKF-UHFFFAOYSA-N 4-methyl-N-[3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyridin-3-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=CC(=CC=C12)C(=O)NC1=CC(=CC(=C1)C(F)(F)F)CN1CCN(CC1)C)C=1C=NC=CC=1 DXOMFAFXHKRMKF-UHFFFAOYSA-N 0.000 claims description 3
- YXESXLYKZKCWFJ-UHFFFAOYSA-N 4-methyl-N-[3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(CN2CCN(C)CC2)=CC(=C1)C(F)(F)F)C1=CN=CN=C1 YXESXLYKZKCWFJ-UHFFFAOYSA-N 0.000 claims description 3
- FFGQCLBVJOIXHC-UHFFFAOYSA-N 4-methyl-N-[3-[(4-methylpiperazin-1-yl)methyl]-5-phenylphenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(CN2CCN(C)CC2)=CC(=C1)C1=CC=CC=C1)C1=CN=CN=C1 FFGQCLBVJOIXHC-UHFFFAOYSA-N 0.000 claims description 3
- YVFSNJNTIVOKAV-UHFFFAOYSA-N 4-methyl-N-[3-[(4-methylpiperazin-1-yl)methyl]-5-propan-2-ylphenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC(C)C1=CC(CN2CCN(C)CC2)=CC(NC(=O)C2=CC3=C(C=C2)C(C)CN(C3)C2=CN=CN=C2)=C1 YVFSNJNTIVOKAV-UHFFFAOYSA-N 0.000 claims description 3
- OPEMWSXQLXWPSB-UHFFFAOYSA-N 4-methyl-N-[3-[2-(4-methylpiperazin-1-yl)ethyl]-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(CCN2CCN(C)CC2)=CC(=C1)C(F)(F)F)C1=CN=CN=C1 OPEMWSXQLXWPSB-UHFFFAOYSA-N 0.000 claims description 3
- PGNPRFGVXQKJFG-UHFFFAOYSA-N 4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(=C(CN2CCN(C)CC2)C=C1)C(F)(F)F)C1=CN=CN=C1 PGNPRFGVXQKJFG-UHFFFAOYSA-N 0.000 claims description 3
- XRLKUJVAKVKVMM-UHFFFAOYSA-N 4-methyl-N-[4-methyl-3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=CC(=CC=C12)C(=O)NC1=CC(=C(C(=C1)C(F)(F)F)C)CN1CCN(CC1)C)C=1C=NC=NC=1 XRLKUJVAKVKVMM-UHFFFAOYSA-N 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- NFZXBQXIWXZUDR-UHFFFAOYSA-N N-[3-[(4-cyclohexylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]-4-methyl-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(CN2CCN(CC2)C2CCCCC2)=CC(=C1)C(F)(F)F)C1=CN=CN=C1 NFZXBQXIWXZUDR-UHFFFAOYSA-N 0.000 claims description 3
- QIYCVICASXFGFF-UHFFFAOYSA-N N-[3-[(4-ethylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]-4-methyl-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CCN1CCN(CC2=CC(=CC(NC(=O)C3=CC4=C(C=C3)C(C)CN(C4)C3=CN=CN=C3)=C2)C(F)(F)F)CC1 QIYCVICASXFGFF-UHFFFAOYSA-N 0.000 claims description 3
- SSHLZMDEQQUFCQ-UHFFFAOYSA-N N-[3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyridin-3-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CN1CCN(CC2=CC(=CC(NC(=O)C3=CC4=C(CCN(C4)C4=CC=CN=C4)C=C3)=C2)C(F)(F)F)CC1 SSHLZMDEQQUFCQ-UHFFFAOYSA-N 0.000 claims description 3
- HDTCSYZQKDPDHW-UHFFFAOYSA-N N-[3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CN1CCN(CC2=CC(=CC(NC(=O)C3=CC4=C(CCN(C4)C4=CN=CN=C4)C=C3)=C2)C(F)(F)F)CC1 HDTCSYZQKDPDHW-UHFFFAOYSA-N 0.000 claims description 3
- OWGUHYJAQKOTEZ-UHFFFAOYSA-N N-[3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]-2-quinolin-3-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CN1CCN(CC2=CC(=CC(NC(=O)C3=CC4=C(CCN(C4)C4=CC5=CC=CC=C5N=C4)C=C3)=C2)C(F)(F)F)CC1 OWGUHYJAQKOTEZ-UHFFFAOYSA-N 0.000 claims description 3
- TZIWJRRYZAJZHK-UHFFFAOYSA-N N-[3-[(dimethylamino)methyl]-5-(trifluoromethyl)phenyl]-4-methyl-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(CN(C)C)=CC(=C1)C(F)(F)F)C1=CN=CN=C1 TZIWJRRYZAJZHK-UHFFFAOYSA-N 0.000 claims description 3
- COPFQQYHJSJTAB-BIAFCPFJSA-N N-[3-[[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl]-5-(trifluoromethyl)phenyl]-4-methyl-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(CN2CC[C@@H](C2)N(C)C)=CC(=C1)C(F)(F)F)C1=CN=CN=C1 COPFQQYHJSJTAB-BIAFCPFJSA-N 0.000 claims description 3
- CNNKHMDQQCORDW-UHFFFAOYSA-N N-[3-[[2-(dimethylamino)ethyl-methylamino]methyl]-5-(trifluoromethyl)phenyl]-4-methyl-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(CN(C)CCN(C)C)=CC(=C1)C(F)(F)F)C1=CN=CN=C1 CNNKHMDQQCORDW-UHFFFAOYSA-N 0.000 claims description 3
- RFKIMRWCLPYQNL-UHFFFAOYSA-N N-[3-cyclohexyl-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-methyl-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(=CC(CN2CCN(C)CC2)=C1)C1CCCCC1)C1=CN=CN=C1 RFKIMRWCLPYQNL-UHFFFAOYSA-N 0.000 claims description 3
- GMHKDZXPTJDOJO-UHFFFAOYSA-N N-[3-cyclopentyl-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-methyl-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(=CC(CN2CCN(C)CC2)=C1)C1CCCC1)C1=CN=CN=C1 GMHKDZXPTJDOJO-UHFFFAOYSA-N 0.000 claims description 3
- HETHIRVCVHMSMQ-UHFFFAOYSA-N N-[3-cyclopropyl-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-methyl-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(=CC(CN2CCN(C)CC2)=C1)C1CC1)C1=CN=CN=C1 HETHIRVCVHMSMQ-UHFFFAOYSA-N 0.000 claims description 3
- ADPNSUYZISECKN-UHFFFAOYSA-N N-[3-ethyl-5-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-methyl-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CCC1=CC(CN2CCN(C)CC2)=CC(NC(=O)C2=CC3=C(C=C2)C(C)CN(C3)C2=CN=CN=C2)=C1 ADPNSUYZISECKN-UHFFFAOYSA-N 0.000 claims description 3
- KZJMAYVZYCIFHX-UHFFFAOYSA-N N-[4-chloro-3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]-4-methyl-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(CN2CCN(C)CC2)=C(Cl)C(=C1)C(F)(F)F)C1=CN=CN=C1 KZJMAYVZYCIFHX-UHFFFAOYSA-N 0.000 claims description 3
- PVWUUXNRYZSAHN-UHFFFAOYSA-N N-[4-fluoro-3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]-4-methyl-2-pyrimidin-5-yl-3,4-dihydro-1H-isoquinoline-7-carboxamide Chemical compound CC1CN(CC2=C1C=CC(=C2)C(=O)NC1=CC(CN2CCN(C)CC2)=C(F)C(=C1)C(F)(F)F)C1=CN=CN=C1 PVWUUXNRYZSAHN-UHFFFAOYSA-N 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 231100000241 scar Toxicity 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- ABDMQSFNJPYOLA-UHFFFAOYSA-N NS(=O)(=O)[N+]([O-])=O Chemical compound NS(=O)(=O)[N+]([O-])=O ABDMQSFNJPYOLA-UHFFFAOYSA-N 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000000277 Splenic Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 208000024558 digestive system cancer Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010231 gastrointestinal system cancer Diseases 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000007913 intrathecal administration Methods 0.000 claims description 2
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000002262 irrigation Effects 0.000 claims description 2
- 238000003973 irrigation Methods 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 2
- 210000002200 mouth mucosa Anatomy 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 210000002850 nasal mucosa Anatomy 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 201000002471 spleen cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 208000037964 urogenital cancer Diseases 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 7
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 1
- 206010039580 Scar Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 36
- 150000002431 hydrogen Chemical class 0.000 description 7
- 0 CCC(C)CCC(N(*)C(C)(CC(C)(C)CNC(C)C)O)=*C Chemical compound CCC(C)CCC(N(*)C(C)(CC(C)(C)CNC(C)C)O)=*C 0.000 description 6
- 239000002777 nucleoside Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 150000003833 nucleoside derivatives Chemical class 0.000 description 5
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 229940123237 Taxane Drugs 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
- 229960005277 gemcitabine Drugs 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 description 2
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- MAKIFUSFBGUARO-QTDGRNKISA-N CC(CN(C(C1=CC(CN(CC2)C[C@@H]2N(C)C)=CC(C(F)(F)F)=C1)C1=C2)C3=CN=CN=C3)C1=CC=C2C(N)=O Chemical compound CC(CN(C(C1=CC(CN(CC2)C[C@@H]2N(C)C)=CC(C(F)(F)F)=C1)C1=C2)C3=CN=CN=C3)C1=CC=C2C(N)=O MAKIFUSFBGUARO-QTDGRNKISA-N 0.000 description 1
- 101100498819 Caenorhabditis elegans ddr-1 gene Proteins 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000003835 nucleoside group Chemical class 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462067070P | 2014-10-22 | 2014-10-22 | |
| US62/067,070 | 2014-10-22 | ||
| US201562204176P | 2015-08-12 | 2015-08-12 | |
| US62/204,176 | 2015-08-12 | ||
| PCT/US2015/056611 WO2016064970A1 (en) | 2014-10-22 | 2015-10-21 | Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018502900A JP2018502900A (ja) | 2018-02-01 |
| JP2018502900A5 true JP2018502900A5 (enExample) | 2018-11-22 |
Family
ID=55761466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540966A Pending JP2018502900A (ja) | 2014-10-22 | 2015-10-21 | ジスコイジンドメイン受容体１を標的化する小分子阻害剤およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10370360B2 (enExample) |
| EP (1) | EP3209299A4 (enExample) |
| JP (1) | JP2018502900A (enExample) |
| CN (1) | CN107206004A (enExample) |
| AU (1) | AU2015335980A1 (enExample) |
| CA (1) | CA2965336A1 (enExample) |
| WO (1) | WO2016064970A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS59007B1 (sr) | 2014-02-03 | 2019-08-30 | Vitae Pharmaceuticals Llc | Dihidropirolopiridinski inhibitori ror-gama |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| WO2017024018A1 (en) | 2015-08-05 | 2017-02-09 | Vitae Pharmaceuticals, Inc. | Modulators of ror-gamma |
| KR20180086221A (ko) * | 2015-11-20 | 2018-07-30 | 비타이 파마슈티컬즈, 인코포레이티드 | Ror-감마의 조절물질 |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| CN108276388B (zh) * | 2017-03-10 | 2020-01-14 | 成都医学院 | 1h-吲哚类衍生物及其用途 |
| TWI676482B (zh) * | 2017-03-23 | 2019-11-11 | 高雄醫學大學 | 盤基蛋白結構域受體１的抑制劑及活化劑及其用途 |
| US12133896B2 (en) | 2017-03-23 | 2024-11-05 | Kaohsiung Medical University | Methods for treating or alleviating a bone-loss related disease or condition by administering a nucleic acid encoding a discoidin domain receptor 1 (DDR1) protein |
| WO2018214862A1 (zh) * | 2017-05-23 | 2018-11-29 | 江苏恒瑞医药股份有限公司 | 螺环甲酰胺类衍生物、其制备方法及其在医药上的应用 |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| MA49685A (fr) | 2017-07-24 | 2021-04-14 | Vitae Pharmaceuticals Llc | INHIBITEURS DE ROR gamma |
| KR102066402B1 (ko) * | 2017-12-22 | 2020-01-15 | 대화제약 주식회사 | 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물 |
| CN108624590A (zh) * | 2018-04-19 | 2018-10-09 | 西安医学院 | 一种抑制DDR2表达的siRNA及其应用 |
| US20210244737A1 (en) * | 2018-06-20 | 2021-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions for treating melanoma |
| CN111217748B (zh) * | 2018-11-23 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 一种螺环二氢异喹啉甲酰胺类衍生物的晶型及其制备方法 |
| WO2021239643A1 (en) | 2020-05-25 | 2021-12-02 | Chiesi Farmaceutici S.P.A. | Benzylamine derivatives as ddrs inhibitors |
| GB202010464D0 (en) * | 2020-07-08 | 2020-08-19 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| CN112321591B (zh) * | 2020-11-03 | 2022-11-08 | 中国药科大学 | 盘状结构域受体1蛋白抑制剂、制备方法及应用 |
| WO2022128850A1 (en) * | 2020-12-16 | 2022-06-23 | Galapagos Nv | Novel isoquinoline derivatives and pharmaceutical copositions thereof for the treatment of diseases |
| IL306062A (en) | 2021-03-26 | 2023-11-01 | Chiesi Farm Spa | Tetrahydrothieno pyridine derivatives as ddrs inhibitors |
| WO2022200576A1 (en) | 2021-03-26 | 2022-09-29 | Chiesi Farmaceutici S.P.A. | Indoline derivatives as ddr1 and ddr2 inhibitors |
| PL4313972T3 (pl) | 2021-03-26 | 2025-06-09 | Chiesi Farmaceutici S.P.A. | Pochodne indolinowe jako inhibitory ddr |
| JP2024510849A (ja) * | 2021-03-26 | 2024-03-11 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｄｄｒ阻害剤としてのテトラヒドロチエノピリジン誘導体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA001539B1 (ru) | 1996-11-27 | 2001-04-23 | Пфайзер Инк. | Амиды, ингибирующие секрецию аполипопротеина в (аро в) и/или микросомного протеина переноса триглицеридов (мтр) |
| IN188411B (enExample) * | 1997-03-27 | 2002-09-21 | Yuhan Corp | |
| EP1723134A2 (en) * | 2004-02-18 | 2006-11-22 | Pfizer Products Incorporated | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| CN102317269B (zh) * | 2009-02-11 | 2015-06-17 | 默克专利有限公司 | 新氨基氮杂杂环甲酰胺类 |
| TW201206444A (en) * | 2010-05-11 | 2012-02-16 | Sanofi Aventis | Substituted N-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof |
| CN103965195B (zh) * | 2013-02-01 | 2016-09-28 | 中国科学院广州生物医药与健康研究院 | 用于盘状结构域受体小分子抑制剂的化合物及其应用 |
| WO2014167444A1 (en) * | 2013-04-08 | 2014-10-16 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS |
-
2015
- 2015-10-21 CA CA2965336A patent/CA2965336A1/en not_active Abandoned
- 2015-10-21 AU AU2015335980A patent/AU2015335980A1/en not_active Abandoned
- 2015-10-21 WO PCT/US2015/056611 patent/WO2016064970A1/en not_active Ceased
- 2015-10-21 EP EP15852998.2A patent/EP3209299A4/en not_active Withdrawn
- 2015-10-21 JP JP2017540966A patent/JP2018502900A/ja active Pending
- 2015-10-21 US US15/521,107 patent/US10370360B2/en active Active
- 2015-10-21 CN CN201580067710.9A patent/CN107206004A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502900A5 (enExample) | ||
| ES2400070T3 (es) | Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos | |
| JP2013056930A5 (enExample) | ||
| JPWO2021085653A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| JP2009513703A5 (enExample) | ||
| US12187720B2 (en) | Compounds for treatment of cancer | |
| JP2016519653A5 (enExample) | ||
| HRP20141094T1 (hr) | 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze | |
| JP2014518544A5 (enExample) | ||
| US20080207572A1 (en) | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | |
| JP2015521166A5 (enExample) | ||
| JP2016528197A5 (enExample) | ||
| JP2012502927A5 (enExample) | ||
| JP2013522310A (ja) | Ｈｅｃ１活性の調節因子およびそのための方法 | |
| RU2013144571A (ru) | Алинзамещенные хиназолины и способы их применения | |
| AU2012273133A1 (en) | Heterocyclic compounds for treating helminth infections | |
| JP2013516480A5 (enExample) | ||
| US8802692B2 (en) | Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents | |
| ES2440799T3 (es) | Métodos para tratar cáncer resistente a los fármacos | |
| JP2006516626A5 (enExample) | ||
| US11485711B2 (en) | Compounds for inhibiting TNIK and medical uses thereof | |
| RU2758259C2 (ru) | Соединение формулы (I), фармацевтическая композиция, применение соединения формулы (I) для лечения гематологических и/или пролиферативных нарушений | |
| AU2014280354A1 (en) | Combinations for the treatment of cancer comprising a Mps-1 kinase inhibitor and a mitotic inhibitor | |
| JP2016502540A5 (enExample) |